• Leahy, making sure that the government does not have to disclose any information under the Freedom of Information Act relating to drug inspections from a foreign government agency;
• Sen. Rob PortmanRob PortmanRyan tries to save tax plan Rift in GOP threatens ObamaCare repeal Overnight Tech: GOP split on net neutrality strategy | Trump's phone worries Dems | Bill in the works on self-driving cars MORE (R-Ohio), directing the attorney general to establish uniform standards for the exchange of controlled substance and prescription information for the purpose of preventing diversion, fraud and abuse of controlled substances and other prescription drugs; and,
• Sen. Tom CoburnTom CoburnCoburn: Trump's tweets aren't presidential The road ahead for America’s highways Rethinking taxation MORE (R-Okla.), to require an independent assessment of the FDA's review of drug applications.
Harkin also announced that another amendment from Coburn would be withdrawn — a proposal to require the Health and Human Services secretary to ensure that performance awards are connected to employee evaluations.
Senate Majority Leader Harry ReidHarry ReidIf Gorsuch pick leads to 'crisis,' Dems should look in mirror first Senate confirms Mulvaney to be Trump’s budget chief Democrats declare victory after Puzder bows out MORE (D-Nev.) said Thursday morning that he hoped some of the remaining 11 amendments to the FDA bill could be handled quickly. With the four unanimous consent votes, seven roll-call votes remain before final passage. These votes are scheduled for 2 p.m., but Reid said he hoped they might start earlier.